Genome-wide Association Study

Samsung Medical Center

Overview

To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.

Study Type

OBSERVATIONAL

Conditions

Esophageal Squamous Cell Carcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological confirmed esophageal squamous cell carcinoma * Patients treated with Taxane or 5-FU or platinum based chemotherapy. * provision of a signed written informed consent. Exclusion Criteria: * patients not signed written informed consent. * patient unacceptable for study in the judgement of the investigator.

Locations (1)

Samsung medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Biomarkers predictive

Biomarkers predictive of clinical response to Taxane or 5-fluorouracil or platinum based chemotherapy.

Time frame: 24months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.